Last reviewed · How we verify

Preservative-free latanoprost — Competitive Intelligence Brief

Preservative-free latanoprost (Preservative-free latanoprost) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F analog. Area: Ophthalmology.

marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Preservative-free latanoprost (Preservative-free latanoprost) — Association for Innovation and Biomedical Research on Light and Image. Latanoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Preservative-free latanoprost TARGET Preservative-free latanoprost Association for Innovation and Biomedical Research on Light and Image marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor)
travoprost 0.004% (drug) travoprost 0.004% (drug) University Hospital, Basel, Switzerland marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor)
Generic travoprost Generic travoprost Université de Sherbrooke marketed Prostaglandin F analog Prostaglandin F (FP) receptor
travatan 0.004% travatan 0.004% Allergan marketed Prostaglandin F analog Prostaglandin F (FP) receptor
Bimatoprost Vehicle Bimatoprost Vehicle Allergan marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor)
Brand-name latanoprost Brand-name latanoprost CHU de Quebec-Universite Laval marketed Prostaglandin F analog FP prostaglandin receptor
IOPIZE© Latanoprost eyedrops IOPIZE© Latanoprost eyedrops University of Catanzaro marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F analog class)

  1. Allergan · 8 drugs in this class
  2. CHU de Quebec-Universite Laval · 2 drugs in this class
  3. Association for Innovation and Biomedical Research on Light and Image · 2 drugs in this class
  4. Kasr El Aini Hospital · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
  7. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
  8. SpyGlass Pharma, Inc. · 1 drug in this class
  9. Tun Hussein Onn National Eye Hospital · 1 drug in this class
  10. Universitaire Ziekenhuizen KU Leuven · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Preservative-free latanoprost — Competitive Intelligence Brief. https://druglandscape.com/ci/preservative-free-latanoprost. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: